HRP20190793T1 - Spojevi dimetilbenzojeve kiseline - Google Patents
Spojevi dimetilbenzojeve kiseline Download PDFInfo
- Publication number
- HRP20190793T1 HRP20190793T1 HRP20190793TT HRP20190793T HRP20190793T1 HR P20190793 T1 HRP20190793 T1 HR P20190793T1 HR P20190793T T HRP20190793T T HR P20190793TT HR P20190793 T HRP20190793 T HR P20190793T HR P20190793 T1 HRP20190793 T1 HR P20190793T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutically acceptable
- compound
- acceptable salt
- dimethylbenzoic acid
- carbonyl
- Prior art date
Links
- RIZUCYSQUWMQLX-UHFFFAOYSA-N 2,3-dimethylbenzoic acid Chemical class CC1=CC=CC(C(O)=O)=C1C RIZUCYSQUWMQLX-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 9
- SIIGKILIYGRIJN-UHFFFAOYSA-N 3-[[3-(3-chlorophenyl)naphthalene-1-carbonyl]amino]-2,4-dimethylbenzoic acid Chemical compound ClC=1C=C(C=CC1)C=1C=C(C2=CC=CC=C2C1)C(=O)NC=1C(=C(C(=O)O)C=CC1C)C SIIGKILIYGRIJN-UHFFFAOYSA-N 0.000 claims 2
- WXAMQUHPOHAPDV-UHFFFAOYSA-N 3-[[6-(1,3-benzodioxol-5-yl)-3-methylpyridine-2-carbonyl]amino]-2,4-dimethylbenzoic acid Chemical compound O1COC2=C1C=CC(=C2)C2=CC=C(C(=N2)C(=O)NC=2C(=C(C(=O)O)C=CC2C)C)C WXAMQUHPOHAPDV-UHFFFAOYSA-N 0.000 claims 2
- WRBLOVAXQYYLFM-UHFFFAOYSA-N 3-[[6-[3-(hydroxymethyl)phenyl]-3-methylpyridine-2-carbonyl]amino]-2,4-dimethylbenzoic acid Chemical compound CC1=CC=C(C(O)=O)C(C)=C1NC(=O)C1=NC(C=2C=C(CO)C=CC=2)=CC=C1C WRBLOVAXQYYLFM-UHFFFAOYSA-N 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/84—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/81—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
- C07D215/52—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4 with aryl radicals attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Claims (9)
1. Spoj, naznačen time što ga se bira između:
3-[[6-(1,3-benzodioksol-5-il)-3-metilpiridin-2-karbonil]amino]-2,4-dimetilbenzojeve kiseline;
3-[[6-[3-(hidroksimetil)fenil]-3-metilpiridin-2-karbonil]amino]-2,4-dimetilbenzojeve kiseline; i
3-[[3-(3-klorfenil)naftalen-1-karbonil]amino]-2,4-dimetilbenzojeve kiseline;
ili njihovih farmaceutski prihvatljivih soli.
2. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je 3-[[6-(1,3-benzodioksol-5-il)-3-metilpiridin-2-karbonil]amino]-2,4-dimetilbenzojeva kiselina;
ili njezina farmaceutski prihvatljiva sol.
3. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je 3-[[6-[3-(hidroksimetil)fenil]-3-metilpiridin-2-karbonil]amino]-2,4-dimetilbenzojeva kiselina;
ili njezina farmaceutski prihvatljiva sol.
4. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je 3-[[3-(3-klorfenil)naftalen-1-karbonil]amino]-2,4-dimetilbenzojeva kiselina;
ili njezina farmaceutski prihvatljiva sol.
5. Spoj, ili njegova farmaceutski prihvatljiva sol, u skladu s patentnim zahtjevima 1 do 4, naznačen time što je namijenjen upotrebi u terapiji.
6. Spoj, ili njegova farmaceutski prihvatljiva sol, u skladu s patentnim zahtjevima 1 do 4, naznačen time što je namijenjen upotrebi u liječenju osteoartritisa.
7. Spoj, ili njegova farmaceutski prihvatljiva sol, u skladu s patentnim zahtjevima 1 do 4, naznačen time što je namijenjen upotrebi u liječenju reumatoidnog artritisa.
8. Spoj, ili njegova farmaceutski prihvatljiva sol, u skladu s patentnim zahtjevima 1 do 4, naznačen time što je namijenjen upotrebi u liječenju boli povezane s osteoartritisom ili reumatoidnim artritisom.
9. Farmaceutski pripravak, naznačen tome što sadrži spoj, ili njegovu farmaceutski prihvatljivu sol, u skladu s patentnim zahtjevima 1 do 4, uz jednu ili više farmaceutski prihvatljivih podloga, razrjeđivača ili pomoćnih tvari.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361916824P | 2013-12-17 | 2013-12-17 | |
PCT/US2014/069783 WO2015094912A1 (en) | 2013-12-17 | 2014-12-11 | Dimethylbenzoic acid compounds |
EP14827908.6A EP3083554B1 (en) | 2013-12-17 | 2014-12-11 | Dimethylbenzoic acid compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20190793T1 true HRP20190793T1 (hr) | 2019-06-28 |
Family
ID=52355186
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20190793TT HRP20190793T1 (hr) | 2013-12-17 | 2019-04-29 | Spojevi dimetilbenzojeve kiseline |
Country Status (23)
Country | Link |
---|---|
US (1) | US10005721B2 (hr) |
EP (1) | EP3083554B1 (hr) |
JP (1) | JP6200596B2 (hr) |
KR (1) | KR101937186B1 (hr) |
CN (1) | CN105793236B (hr) |
AU (1) | AU2014366371B2 (hr) |
CA (1) | CA2929562A1 (hr) |
CY (1) | CY1121677T1 (hr) |
DK (1) | DK3083554T3 (hr) |
EA (1) | EA028675B1 (hr) |
ES (1) | ES2727329T3 (hr) |
HR (1) | HRP20190793T1 (hr) |
HU (1) | HUE043614T2 (hr) |
LT (1) | LT3083554T (hr) |
ME (1) | ME03398B (hr) |
MX (1) | MX368178B (hr) |
PL (1) | PL3083554T3 (hr) |
PT (1) | PT3083554T (hr) |
RS (1) | RS58594B1 (hr) |
SA (1) | SA516371324B1 (hr) |
SI (1) | SI3083554T1 (hr) |
TR (1) | TR201904327T4 (hr) |
WO (1) | WO2015094912A1 (hr) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3191452A1 (de) * | 2014-09-09 | 2017-07-19 | Bayer Pharma Aktiengesellschaft | Substituierte n,2-diarylchinolin-4-carboxamide und ihre anti-inflammatorische verwendung |
US10745382B2 (en) * | 2015-10-15 | 2020-08-18 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
WO2017153235A1 (de) * | 2016-03-09 | 2017-09-14 | Bayer Pharma Aktiengesellschaft | Substituierte n-cyclo-3-aryl-1-naphthamide und ihre verwendung |
JP7107963B2 (ja) | 2017-04-10 | 2022-07-27 | バイエル・アクチエンゲゼルシヤフト | 置換されたn-アリールエチル-2-アリールキノリン-4-カルボキサミド類及びそれの使用 |
TWI770157B (zh) | 2017-04-10 | 2022-07-11 | 德商拜耳廠股份有限公司 | 經取代之n-芳基乙基-2-胺基喹啉-4-甲醯胺及其用途 |
DK3625228T3 (da) | 2017-05-18 | 2021-10-11 | Idorsia Pharmaceuticals Ltd | Pyrimidinderivater som pge2-receptormodulatorer |
WO2018210987A1 (en) | 2017-05-18 | 2018-11-22 | Idorsia Pharmaceuticals Ltd | Benzofurane and benzothiophene derivatives as pge2 receptor modulators |
UA124748C2 (uk) | 2017-05-18 | 2021-11-10 | Ідорсія Фармасьютікалз Лтд | N-заміщені індольні похідні |
AR111941A1 (es) | 2017-05-18 | 2019-09-04 | Idorsia Pharmaceuticals Ltd | Derivados de pirimidina como moduladores del receptor de pge2 |
CA3063788A1 (en) | 2017-05-18 | 2018-11-22 | Idorsia Pharmaceuticals Ltd | Pyrimidine derivatives |
US20220064113A1 (en) * | 2019-01-22 | 2022-03-03 | Keythera (Suzhou) Pharmaceuticals Co. Ltd. | Compound for inhibiting pge2/ep4 signaling transduction inhibiting, preparation method therefor, and medical uses thereof |
JPWO2022102731A1 (hr) | 2020-11-13 | 2022-05-19 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1270615B (it) | 1994-07-14 | 1997-05-07 | Smithkline Beecham Farma | Uso di derivati di chinolina |
TW502026B (en) * | 1995-06-20 | 2002-09-11 | Zeneca Ltd | Aromatic compounds useful as antagonists of e-type prostaglandins, processes for the preparation thereof, pharmaceutical compositions comprising the compounds, and intermediates |
BR0009041A (pt) * | 1999-03-17 | 2001-12-26 | Astrazeneca Ab | Derivado de amida, processo para a preparação deum derivado de amida, composição farmacêutica,uso de um derivado de amida, e, método paratratar doenças ou quadros clìnicos mediados porcitocinas |
WO2005021508A1 (en) * | 2003-09-03 | 2005-03-10 | Pfizer Inc. | Phenyl or pyridyl amide compounds as prostaglandin e2 antagonists |
WO2005030753A2 (en) | 2003-09-22 | 2005-04-07 | Euro-Celtique S.A. | Therapeutic agents useful for treating pain |
GB0324269D0 (en) * | 2003-10-16 | 2003-11-19 | Pharmagene Lab Ltd | EP4 receptor antagonists |
WO2005080367A1 (en) * | 2004-02-12 | 2005-09-01 | Pharmagene Laboratories Limited | Ep2 receptor agonists |
EP1756043B1 (en) * | 2004-05-04 | 2009-07-01 | RaQualia Pharma Inc | Ortho substituted aryl or heteroaryl amide compounds |
US20070054916A1 (en) * | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
JP5183628B2 (ja) * | 2006-06-12 | 2013-04-17 | メルク カナダ インコーポレイテッド | Ep4受容体リガンドとしてのインドリンアミド誘導体 |
WO2009005076A1 (ja) * | 2007-07-03 | 2009-01-08 | Astellas Pharma Inc. | アミド化合物 |
WO2010043592A1 (en) | 2008-10-15 | 2010-04-22 | Revotar Biopharmaceuticals Ag | Lipase inhibitors for use for the treatment of obesity |
KR20110110286A (ko) * | 2009-01-30 | 2011-10-06 | 토야마 케미칼 컴퍼니 리미티드 | N-아실 안트라닐산 유도체 또는 그 염 |
EP2607348B8 (en) * | 2009-03-31 | 2021-04-21 | Renascience Inc. | Plasminogen Activator Inhibitor-1 Inhibitor |
WO2012004293A2 (de) | 2010-07-08 | 2012-01-12 | Bayer Cropscience Ag | Insektizide und fungizide wirkstoffkombinationen |
US20140057953A1 (en) | 2011-03-03 | 2014-02-27 | Rolf Hartmann | Biaryl derivatives as selective 17beta-hydroxysteroid dehydrogenase type 2 inhibitors |
JP2014525426A (ja) * | 2011-08-31 | 2014-09-29 | アマケン エンヴェー | 新規のソフトrock阻害剤 |
AU2012307527B2 (en) * | 2011-09-16 | 2017-07-20 | Sanofi | Aniline derivatives,their preparation and their therapeutic application |
TWI572597B (zh) | 2012-06-29 | 2017-03-01 | 美國禮來大藥廠 | 二甲基-苯甲酸化合物 |
EP2765128A1 (en) * | 2013-02-07 | 2014-08-13 | Almirall, S.A. | Substituted benzamides with activity towards EP4 receptors |
-
2014
- 2014-12-11 AU AU2014366371A patent/AU2014366371B2/en not_active Ceased
- 2014-12-11 WO PCT/US2014/069783 patent/WO2015094912A1/en active Application Filing
- 2014-12-11 EP EP14827908.6A patent/EP3083554B1/en active Active
- 2014-12-11 PT PT14827908T patent/PT3083554T/pt unknown
- 2014-12-11 RS RS20190469A patent/RS58594B1/sr unknown
- 2014-12-11 CN CN201480066576.6A patent/CN105793236B/zh not_active Expired - Fee Related
- 2014-12-11 TR TR2019/04327T patent/TR201904327T4/tr unknown
- 2014-12-11 CA CA2929562A patent/CA2929562A1/en not_active Abandoned
- 2014-12-11 US US15/030,891 patent/US10005721B2/en not_active Expired - Fee Related
- 2014-12-11 PL PL14827908T patent/PL3083554T3/pl unknown
- 2014-12-11 SI SI201431139T patent/SI3083554T1/sl unknown
- 2014-12-11 ME MEP-2019-106A patent/ME03398B/me unknown
- 2014-12-11 MX MX2016007861A patent/MX368178B/es active IP Right Grant
- 2014-12-11 DK DK14827908.6T patent/DK3083554T3/da active
- 2014-12-11 HU HUE14827908A patent/HUE043614T2/hu unknown
- 2014-12-11 LT LTEP14827908.6T patent/LT3083554T/lt unknown
- 2014-12-11 ES ES14827908T patent/ES2727329T3/es active Active
- 2014-12-11 KR KR1020167015772A patent/KR101937186B1/ko active IP Right Grant
- 2014-12-11 EA EA201690911A patent/EA028675B1/ru not_active IP Right Cessation
- 2014-12-11 JP JP2016538636A patent/JP6200596B2/ja not_active Expired - Fee Related
-
2016
- 2016-06-14 SA SA516371324A patent/SA516371324B1/ar unknown
-
2019
- 2019-04-29 HR HRP20190793TT patent/HRP20190793T1/hr unknown
- 2019-05-08 CY CY20191100495T patent/CY1121677T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
CY1121677T1 (el) | 2020-07-31 |
SA516371324B1 (ar) | 2018-03-22 |
RS58594B1 (sr) | 2019-05-31 |
PL3083554T3 (pl) | 2019-08-30 |
LT3083554T (lt) | 2019-05-10 |
ME03398B (me) | 2020-01-20 |
EA028675B1 (ru) | 2017-12-29 |
TR201904327T4 (tr) | 2019-04-22 |
KR20160086905A (ko) | 2016-07-20 |
AU2014366371B2 (en) | 2017-02-16 |
DK3083554T3 (da) | 2019-05-13 |
PT3083554T (pt) | 2019-06-11 |
JP6200596B2 (ja) | 2017-09-20 |
JP2017500309A (ja) | 2017-01-05 |
CN105793236A (zh) | 2016-07-20 |
EA201690911A1 (ru) | 2016-09-30 |
EP3083554B1 (en) | 2019-03-13 |
ES2727329T3 (es) | 2019-10-15 |
EP3083554A1 (en) | 2016-10-26 |
MX368178B (es) | 2019-09-23 |
US20160251306A1 (en) | 2016-09-01 |
CN105793236B (zh) | 2017-10-10 |
HUE043614T2 (hu) | 2019-08-28 |
US10005721B2 (en) | 2018-06-26 |
WO2015094912A1 (en) | 2015-06-25 |
MX2016007861A (es) | 2017-01-11 |
SI3083554T1 (sl) | 2019-04-30 |
KR101937186B1 (ko) | 2019-01-10 |
CA2929562A1 (en) | 2015-06-25 |
AU2014366371A1 (en) | 2016-05-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20190793T1 (hr) | Spojevi dimetilbenzojeve kiseline | |
CY1123460T1 (el) | Ενωσεις και μεθοδοι για τη θεραπεια μιας επιληπτικης διαταραχης | |
MA37400A1 (fr) | Composés hétérocyclyle en tant qu'inhibiteurs de mek | |
EA201690287A1 (ru) | 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом | |
EA201891191A1 (ru) | 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения | |
CL2015000578A1 (es) | Compuesto n-(2-(6-fluoro-1-h-indol-3-il)etil)-3-(2,2,3,3-tetrafluoropropoxi)bencilamina o su sal, antagonista del receptor 5-ht6; composicion farmaceutica; uso en el tratamiento de la enfermedad de alzheimer. | |
EA201590371A1 (ru) | 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний | |
EA201290860A1 (ru) | Лечение ревматоидного артрита комбинацией лаквинимода и метотрексата | |
EA201590748A1 (ru) | Противовирусные соединения против rsv | |
BR112016011065A8 (pt) | composto cristalino, composição farmacêutica, forma de dosagem, método para tratar anemia | |
BR112015006341A2 (pt) | compostos, composição farmacêutica, método para tratar condição fibrótica, quantidade terapeuticamente efetiva de composto, de sal farmaceuticamente aceitável deste ou de composição farmacêutica e usos das mesmas e de compostos e/ou composição farmacêutica | |
EA201391568A1 (ru) | Новые производные имидазола, подходящие для лечения артрита | |
EA201592250A1 (ru) | Пиразолопирролидиновые производные и их применение в лечение заболеваний | |
EA201790246A1 (ru) | Гетероциклические карбоновые кислоты в качестве активаторов растворимой гуанилатциклазы | |
EA201592256A1 (ru) | Производные имидазопирролидинона и их применение при лечении заболеваний | |
EA201591363A1 (ru) | Аналоги тиадиазола и способы лечения состояний, связанных с дефицитом smn | |
EA201490647A1 (ru) | Производные бензотиазол-6-илуксусной кислоты и их применение для лечения вич-инфекции | |
EA201890771A1 (ru) | Соли и твердые формы монобактамного антибиотика | |
CL2015001643A1 (es) | Formas cristalinas de 3-(imidazo[1,2-b]piridazin-3-iletinil)-4-metil-n-{4-[(4-metilpiperazin-1-il)metil]-3-(trifluorometil)fenil}benzamida y su sal monoclorhidrato; composicion farmaceutica que las comprende; proceso para preparar la forma cristalina a; y metodo para tratar leucemias seleccionadas de la cml o la ph+ aal. | |
BR112017015852A2 (pt) | forma de cristal, sal hemicálcico, sal hemicálcico di-hidratado, sal monossódico hidratado, sal bissódico monoidratado, sal monossódico anidro e método para preparar o composto 1 | |
EA201591512A9 (ru) | Борсодержащие молекулы, способы и составы | |
EA201691600A1 (ru) | Дигидропиридиноновые ингибиторы mgat2 для применения в лечении метаболических нарушений | |
MX2016005396A (es) | Composiciones para administracion oral de acido zoledronico o compuestos relacionados para tratar enfermedades. | |
MX2019006773A (es) | Dexmedetomidina o medetomidina para uso en el tratamiento de la ansiedad por separacion en perros. | |
MX2015013328A (es) | Uso de antagonistas del receptor de ep4 en el tratamiento de enfermedad de cartilago. |